Percept RC is said to be the only sensing-enabled DBS system that enables the doctor to personalise treatment of patients with epilepsy and movement disorders such as essential tremor, dystonia, and Parkinson's disease
A product shot of Medtronic Percept RC neurostimulator. (Credit: Medtronic)
Healthcare technology company Medtronic has received the US Food and Drug Administration (FDA) approval for its Percept RC deep brain stimulation (DBS) system.
The rechargeable neurostimulator is equipped with the BrainSense technology that captures and records brain signals to adapt and personalise therapy to a patient’s changing needs.
Percept RC is said to be the only sensing-enabled DBS system that enables the doctor to personalise the treatment of patients with epilepsy and movement disorders such as essential tremor, dystonia, and Parkinson’s disease.
The DBS system, claimed to be the smallest and thinnest dual-channel neurostimulator, utilises a medical device that is surgically implanted and resembles a cardiac pacemaker.
The Percept neurostimulators send electrical signals through slender wires to brain targets impacted by neurological disorders.
Medtronic said that the Percept RC battery has 15 years of service life with consistent and fast recharge performance.
The device is part of the Medtronic Percept family, which includes the Percept PC neurostimulator, BrainSense technology, and SenSight directional leads.
Medtronic neuroscience portfolio’s neuromodulation business brain modulation division vice president and general manager Amaza Reitmeier said: “Our DBS therapy with exclusive BrainSense technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments – something many of us unintentionally take for granted.”
In a separate development, the healthcare technology firm secured a CE mark for the MiniMed 780G system with Simplera Sync continuous glucose monitor (CGM).
Simplera Sync is said to be a disposable, all-in-one CGM sensor that requires no fingersticks or overtape.
MiniMed 780G system, Medtronic’s most advanced insulin delivery system, with Simplera Sync is expected to be available across Europe through limited release in spring 2024 for individuals aged more than seven years.
The company will start the phased commercial launch in Europe in the summer of this year.
Medtronic Diabetes EVP and president Que Dallara said: “With the introduction of Simplera Sync sensor, we’re able to offer the proven benefits of our MiniMed 780G system with our newest and most comfortable sensor that can be applied in under 10 seconds.”